IP Verse

Cabazitaxel And Its Use For Treating Cancer

Patent No. EP3294285 (titled "Cabazitaxel And Its Use For Treating Cancer") was filed by Aventis Pharma on May 12, 2016. The application was issued on Dec 18, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATESep 18, 2020UEXKULL & STOLBERG
ZENTIVASep 18, 2020GREINER
STADA ARZNEIMITTELSep 17, 2020HAMM & WITTKOPP
GENERICS UKSep 16, 2020TER MEER STEINMEISTER & PARTNER
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELAug 26, 2020WUNSCHE
FRESENIUS KABI DEUTSCHLANDJul 9, 2020-
HEXALJul 1, 2020MAIWALD
TEVA PHARMACEUTICALSJun 9, 2020LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB
ACCORD HEALTHCAREJun 3, 2020AERA

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Get instant alerts for new documents

EP3294285

AVENTIS PHARMA
Application Number
EP16721844A
Filing Date
May 12, 2016
Status
Revoked
Dec 16, 2022
Publication Date
Dec 18, 2019
External Links
Slate, Register , Google Patents